GeparNuevo Long-Term Analysis: Durvalumab Improves Survival in Early Triple-Negative Breast Cancer
Apr 21, 2026
View online
GeparNuevo Long-Term Analysis: Durvalumab Improves Survival in Early Triple-Negative Breast Cancer
Agenus and BAP Pharma Announce Global Partnership to Expand Authorized Access to BOT+BAL
Margaret Foti and AACR Delegates Thank Congress for Protecting NIH/NCI Funding
Ruiling Yuan: Another Successful Annual Rural Oncology Conference
Christopher Danes: A New Chapter After 16 Years at Takeda
Acute Myeloid Leukemia (AML) in 2026: The Current Landscape and Future Perspectives
AACR Annual Meeting 2026: NETs Drive Tumor Necrosis and Metastasis in Colorectal Cancer
AACR Immuno‑Oncology Research Fellowship
Damon Runyon–Dale F. Frey Award for Breakthrough Scientists
Escalation or De-Escalation? Strategies in HER2+ Breast Cancer Treatment
Oncology 101: An In-Depth Hematology and Oncology Review for Advanced Practice Providers Spring 2026
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
